Press Releases

Date Title and Summary Additional Formats
Toggle Summary Conatus Pharmaceuticals to Report Fourth Quarter and Full Year 2013 Financial Results
SAN DIEGO, March 20, 2014 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced that it will report financial results for the fourth quarter and full year
View HTML
Toggle Summary Conatus Pharmaceuticals Extends Liver Disease Reach With Phase 2 NAFLD/NASH Trial
SAN DIEGO, March 3, 2014 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced the initiation of a Phase 2 clinical trial of its lead drug candidate,
View HTML
Toggle Summary Conatus Pharmaceuticals to Participate in Upcoming Investor Events
SAN DIEGO, Feb. 20, 2014 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced its scheduled participation in the following investor events in February:
View HTML
Toggle Summary Conatus Pharmaceuticals Appoints Two Additional Independent Board Members
SAN DIEGO, Feb. 10, 2014 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced the appointment of two additional independent members to the Conatus Board of
View HTML
Toggle Summary Conatus Pharmaceuticals to Present at BIO CEO & Investor Conference
SAN DIEGO, Feb. 3, 2014 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced its scheduled presentation to provide an overview of the company's programs and
View HTML
Toggle Summary Conatus Pharmaceuticals Updates Development Strategy and 2014 Milestones
Leveraging Orphan Drug Designation in Clinical Trial for Liver Transplant Recipients
View HTML
Toggle Summary Conatus Pharmaceuticals to Ring The NASDAQ Stock Market Opening Bell in Celebration of 2013 Milestones
-- Live Webcast Available at 9:15 am ET -- SAN DIEGO, Dec. 18, 2013 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, will ring the Opening Bell at the NASDAQ MarketSite
View HTML
Toggle Summary Conatus Pharmaceuticals Receives U.S. Orphan Drug Designation for Emricasan for Treatment of Liver Transplant Recipients With Reestablished Fibrosis
SAN DIEGO, Dec. 2, 2013 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug
View HTML
Toggle Summary Conatus Pharmaceuticals to Present at Piper Jaffray and Oppenheimer Healthcare Conferences in December
SAN DIEGO, Nov. 25, 2013 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced that its management team will present at the following upcoming conferences in
View HTML
Toggle Summary Conatus Pharmaceuticals Announces Third Quarter 2013 Financial Results
Management to Host Conference Call Today at 4:30 pm ET
View HTML